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ABSTRACT
The acquisition of endocrine therapy resistance in estrogen receptor α (ERα) 
breast cancer patients represents a major clinical problem. Notch signalling has 
been extensively linked to breast cancer especially in patients who fail to respond to 
endocrine therapy. Following activation, Notch intracellular domain is released and 
enters the nucleus where activates transcription of target genes. The numerous steps 
that cascade after activation of the receptor complicate using Notch as biomarker. 
Hence, this warrants the development of reliable indicators of Notch activity. DMXL2 
is a novel regulator of Notch signalling not yet investigated in breast cancer. Here, we 
demonstrate that DMXL2 is overexpressed in a subset of endocrine therapy resistant 
breast cancer cell lines where it promotes epithelial to mesenchymal transition 
through hyper-activation of Notch signalling via V-ATPase dependent acidification. 
Following DMXL2 depletion or treatment with Bafilomycin A1, both EMT targets 
and Notch signalling pathway significantly decrease. We show for the first time 
that DMXL2 protein levels are significantly increased in ERα positive breast cancer 
patients that progress after endocrine therapy. Finally, we demonstrate that DMXL2 
is a transmembrane protein with a potential extra-cellular domain. These findings 
identify DMXL2 as a novel, functional biomarker for ERα positive breast cancer.
INTRODUCTION
Notch signalling is frequently deregulated in estro­
gen receptor positive breast cancer and represents a 
challenging but important therapeutic opportunity [1]. 
At least in some respect, difficulties in targeting Notch 
arise from the complex molecular features of this pathway 
[2]. In mammals, there are four Notch receptors and 
five Notch ligands. The activity of both is regulated by 
endocytic trafficking, although the detailed mechanisms 
are yet to be fully defined [3]. Data suggest that defective 
endosomes maturation could cause aberrant Notch 
signalling by interfering with γ-secretase (GS) mediated 
Notch cleavage [4]. At present, Notch can be targeted in 
the clinic with γ-secretase inhibitors (GSI), a series of 
compounds designed to block Notch cleavage and nuclear 
translocation of Notch intracellular domain. Furthermore, 
antibodies against Notch are currently being tested [5] 
although patients reported side effects similar to the ones 
due to the use of GSIs [6]. Notch plays a pivotal role 
in many processes including embryonic development, 
carcinogenesis, cancer stem cells maintenance, 
angiogenesis, and epithelial to mesenchymal transition 
(EMT) [7–13].
Aberrant Notch signalling has been linked to breast 
cancer formation and progression [14]. Breast cancer 
remains a major clinical problem worldwide, accounting 
for over for 23% of all cancer deaths [15]. Nearly 70% 
of breast cancers express estrogen receptor α (ERα) and 
are treated with adjuvant endocrine therapy designed to 
block ERα driven transcriptional programs. Alas, around 
40% of patients evolve resistance to endocrine therapies 
and progress towards more advanced disease [16–18]. 
The mechanisms behind drug resistance have not yet 
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been fully elucidated, although work from our and other 
groups proposes that epigenetic reprogramming leading 
to increased Notch signalling may contribute to it 
[19–21]. Notch involvement in endocrine therapy 
resistance makes it attractive for developing targeted 
therapies. Thus, there is a strong need for Notch based 
biomarkers, especially with potential applicability 
for clinical assays. This prompted us to investigate 
DMXL2, which was recently presented as a novel Notch 
modulator. The DMXL2 gene has been recently described 
as a novel player in Notch signalling, regulating the 
acidification of intracellular compartments through the 
vacuolar protonic pump (V-ATPase) both in Drosophila 
and in mammalian systems [22, 23]. The V-ATPase pump 
plays an important role in vesicular trafficking alongside 
endocytic and exocytic traffic [24]. We investigated 
the role of DMXL2 in the context of endocrine therapy 
resistance using patients’ derived clinical specimens 
and long-term estrogen deprived LTED cells [25–28]. 
Our results demonstrate that DMXL2 regulates Notch 
cleavage and chromatin recruitment, epithelial to 
mesenchymal transition, invasion and migration of 
endocrine therapy resistant breast cancer cells. Hence, 
DMXL2 can be identified as novel biomarker in ERα 
positive breast cancer patients.
RESULTS
Notch signalling is dependent on notch 
accumulation in the chromatin
We have previously shown that Notch signalling 
plays a significant role in the development of endocrine 
therapy resistance [18, 19, 29, 30]. Notch signalling 
is partly dependent on the absolute amounts of Notch 
receptors present in the cells. However, there is substantial 
debate on the importance of different Notch receptors in 
endocrine resistance (reviewed in [31]). We reasoned that 
the rate of Notch activation, via its cleavage, is equally 
important to downstream signalling controlling tumor 
cell growth and survival. To test this, we first quantified 
total Notch levels using two isogenic cell lines: MCF7 
and long-term estrogen deprived (LTED). The latter 
were derived from MCF7 following one year estrogen 
withdrawal to mimic endocrine therapy resistant breast 
cancer [28]. Notably, we find that all the receptors are 
downregulated at the protein level (Figure 1A). Notch1 
is also downregulated at the mRNA level, whereas 
Notch3 and Notch4 mRNA levels are not (Figure 1B). 
Paradoxically, LTED cells contain higher protein levels 
of the Notch target Hey2, a well­characterized estrogen 
Figure 1: Notch pathway is upregulated in LTED and is dependent on DMXL2 overexpression. A–D. Representative 
western blot showing (reported) Notch transmembrane domain (TM) and Notch target Hey2 in MCF7 and LTED cells (clone 1 and 2 
respectively) Membranes were blotted with commercially available antibodies against Notch total level B–E. q(RT) PCR mRNA normalised 
to 28S of Notch receptors and Notch targets C–F. Cells were fractionated and the chromatin fraction was loaded. Membranes were blotted 
with in house-developed antibodies against the intracellular domain (Notch ICD).
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target gene [32] suggesting that receptor levels alone could 
not accurately predict Notch signalling (Figure 1A). LTED 
cells have impaired ERα signalling as a consequence of 
estradiol starvation, thus suggesting that Hey2 may be 
uniquely regulated by Notch in endocrine therapy resistant 
cells. Furthermore, we find that numerous additional Notch 
targets are also transcriptionally upregulated in LTED cells 
despite a general reduction in Notch receptor (Figure 1B). 
The discrepancy between total Notch protein levels and 
Notch target genes might be explained by hyper­activated 
Notch signalling via increased cleavage rates. To test 
this hypothesis, we measured Notch ICDs by chromatin 
fractionation and western blot, using ICD specific 
antibodies, which were designed and fully characterised 
in house (Supplementary Figure S1A–1B). Interestingly, 
we find that the LTED chromatin fraction presents greater 
enrichment for the Notch3 and Notch4 ICDs (Figure 1C). 
Importantly, we also screened a second LTED model, 
derived in a different lab (LTED clone 2) [10]. We confirmed 
that the total amount of Notch is dowregulated at protein 
level (Figure 1D) whereas Notch ICDs are upregulated 
in the chromatin fraction (Figure 1F). We also find Notch 
target genes are transcriptionally upregulated in the second 
clone (Figure 1E) thus confirming hyper-activated Notch 
signalling in endocrine therapy resistant cells.
DMXL2 is over-expressed in metastatic breast 
tumors and is epigenetically activated in 
endocrine therapy resistant (ETR) cell lines
The recent discovery of DMXL2 as novel Notch 
regulator, prompted us to look into clinical setting. We 
built a case set including biopsies from ERα positive 
breast cancer patients treated with endocrine therapies. 
For each patient we measured DMXL2 in untreated 
primary breast cancer samples and matched metastatic 
samples resistant to endocrine therapy using IHC which 
revealed that DMXL2 had a membrane-cytoplasmic 
staining (Figure 2A). Using a pair-wise comparison we 
found a significant increase in DMXL2 staining in the 
metastatic samples (Figure 2B), suggesting that DMXL2 
is upregulated in endocrine therapy resistant cells in vivo. 
Based on our findings in vivo, we decided to explore 
DMXL2 protein levels using a comprehensive panel 
of endocrine resistant cells including MCF7 derived 
tamoxifen or fulvestrant resistant (MCF7-TAMR, MCF7-
FULVR), as well as MCF7 cultured in the absence of 
Estrogen (LTED). In addition, we have analysed two 
LTED-derived models, which also developed sequential 
resistance (LTED-TAMR and LTED-FULVR) [28]. Our 
data indicate that DMXL2 is upregulated in all the LTED 
models (Figure 2C) while MCF7-TAMR and MCF7-
FULVR do not exhibit increased DMXL2 expression 
suggesting endocrine therapy specific modulation of 
DMXL2. In addition, we confirmed that changes in 
DMXL2 expression are not related to different culturing 
conditions (e.g. chronic drug exposure). LTED maintained 
high levels of DMXL2 even in the presence of parental 
MCF7 media (supplemented with E2), thus confirming that 
DMXL2 is not estradiol dependent but it is epigenetically 
stably overexpressed (Figure 2D). We also show that 
DMXL2 is significantly upregulated in the second clone 
(Figure 2E). DMXL2 overexpression is accompanied by 
increased chromatin marks typical of active regulatory 
elements (H3K27ac) at the DMXL2 promoter and nearby 
putative enhancers (Figure 2F). Similarly, the chromatin 
near DMXL2 regulatory elements is more accessible to 
transcription factor regulation in LTED compared to 
MCF7 lines as shown by DNaseI hypersensitivity assays 
followed by next generation sequencing. (DHS-seq, Figure 
2F). All the following experiments were performed using 
LTED clone 1 (henceforth identified as LTED).
DMXL2 depletion impairs notch signalling in 
endocrine therapy resistant cells
Previous evidence suggests that DMXL2 might 
regulate Notch in breast cancer cells and that this regulation 
is dependent on the interaction between DMXL2 and the 
V-ATPase pump. [23, 33]. Initially, we postulated that 
high levels of DMXL2 in endocrine resistant cells lines 
might result in increased Notch signalling. To test the role 
of DMXL2 in Notch signalling in the resistant cells, we 
measured Notch targets following DMXL2 depletion. 
As expected, siRNA mediated DMXL2 knock-down 
(Supplementary Figure S2A) significantly impairs Notch 
downstream signalling (Figure 3A). Furthermore, DMXL2 
depleted LTED display less nuclear Hey2 protein levels 
demonstrating that DMXL2 is required in Notch signalling 
(Figure 3B). Importantly, following DMXL2 depletion 
we show augmented trans-membrane (TM) Notch1 and 
Notch4 at protein and mRNA levels (Figure 3C). Strikingly, 
this is associated with a decrease in the chromatin bound 
Notch intracellular domains (NICDs) (Figure 3D). These 
data strongly suggest that DMXL2 regulates Notch 
cleavage in endocrine therapy resistant breast cancer cell 
lines and mediates NICD chromatin accumulation.
V-ATPase inhibition mimics DMXL2 depletion
DMXL2 has been described as a regulator of the 
V-ATPase pump in drosophila and mammalian systems. 
Furthermore, there is a growing body of evidence 
linking oncogenic Notch signalling to V-ATPase pump 
in mammals. [23, 34, 35]. First, we wanted to confirm 
that DMXL2 is required for V-ATPase activity. To do 
so, we performed DMXL2 depletion and measured pH 
by Lysotracker staining [36]. As expected, LTED cells 
depleted for DMXL2 show reduced Lysotracker staining 
confirming that DMXL2 is a pump regulator (Figure 4A). 
To directly inhibit the pump, we employed Bafilomycin 
A1 [37] and measured pH changes in the intracellular 
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Figure 2: DMXL2 is overexpressed in metastatic tumors resistant to endocrine therapy. A. Primary and matched Metastatic 
samples were processed using DMXL2 IHC B. H scores were plotted. Pair-wise T-test between the average score (3 independent 
scorers, duplicate sections) was used to establish significance. DMXL2 is overexpressed in ETR cells and it is epigenetically activated. 
C. Representative western blot showing DMXL2 is overexpressed in LTED resistant cells. Graph shows protein normalised to loading 
control (Actin). q(RT) PCR mRNA levels normalised to 28S. In (C) cells were cultured as described in material and methods. In D. cells 
were cultured in MCF7 media (3 days). (*) P < 0.05 (**) P < 0.01 (***) P < 0.001 E. Different clone of MCF7 and LTED showing DMXL2 
upregulation. F. Snapshots from DNaseI hypersensitivity site (DHS-seq) and Chip-seq for K27ac histone mark near DMXL2 promoter 
across all 6 breast cancer cell models. Chip-seq tracks display the active regulatory elements near DMXL2 promoter are uniquely found in 
estrogen deprived cell lines (LTED cells), indicating the activation of DMXL2 gene in LTED cells, but not MCF7 cells.
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compartment. Bafilomycin A1 disrupts V-ATPase 
function, as shown by the reduction in Lysotracker 
staining (Figure 4B). These experiments were performed 
using 125 nM Bafilomycin A1, a dose that does not 
affect cell proliferation (data not shown). To confirm 
that Notch signalling is dependent on the V-ATPase 
activity in endocrine therapy resistant breast cancer 
cells, we monitored Notch intracellular domain (NICD) 
accumulation into the chromatin following Bafilomycin 
A1 treatment. We demonstrate that Notch3 and 4-ICD 
stop accumulating in the nucleus in a time dependent 
manner following Bafilomycin A1 treatment (Figure 4C) 
mirroring the effect of DMXL2 depletion (Figure 3D). In 
agreement, Notch targets are transcriptionally silenced 
at the same rate (Figure 4D). To further confirm that 
DMXL2 is upstream of Notch signalling, we performed 
a rescue experiment. We used Bafilomycin A1 to down-
regulated Notch targets and then over-expressed Notch3 
and Notch4ICDs. Notably, we were able to completely 
rescue their expression (Figure 4E). Overall, these data 
strongly suggest that increased Notch signalling in LTED 
is linked to V-ATPase acidification and that this is likely 
to be mediated by DMXL2 overexpression.
DMXL2 over-expression correlates with 
acquisition of EMT phenotype
Within our panel of endocrine therapy specific cells, 
we noticed that LTED were uniquely associated with 
migratory and invasive phenotypes (Nguyen et al. under 
revision). Importantly, Notch signalling has been linked to the 
epithelial to mesenchymal transition (EMT) phenotype [29, 
38]. Transcriptional and protein assays confirm that key EMT 
genes (ZEB1, IQGAP1, CDC42, and CD44) are significantly 
upregulated in LTED cells at mRNA levels and at protein 
levels (ZEB1 and IQGAP1). Moreover, loss of E-Cadherin 
and ZO1, a tight junction marker [39], were downregulated 
thus confirming LTED cells underwent EMT (Figure 5A–
5B). Recently, Tuttle and colleagues proposed that DMXL2 
controls migration in Zebrafish Neural Crest [40] through its 
associated binding partner V-ATPase pump. Therefore we 
hypothesized that overexpressed DMXL2 could play a role 
Figure 3: DMXL2 regulates Notch pathway. A. q(RT) PCR mRNA levels of Notch targets following DMXL2 depletion 
B. Representative immunofluorescence images of Hey2 following siDMXL2 showing Hey2 nuclear signal was impaired. Bars represent 
400 uM C. Representative western blot showing reported TM Notch accumulates following DMXL2 depletion. Antibodies were used as 
in 1A D. Representative blot showing Notch3 and 4ICD reduced chromatin accumulation following siDMXL2. Antibodies were used as in 
2C. Knock down was performed for 48 or 72 hrs (for mRNA or protein extraction respectively). (*) P < 0.05 (**) P < 0.01 (***) P < 0.001. 
Every experiment is an average of three independent experiments. Bars represent standard deviation.
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in determining the invasive behaviour of LTED cell lines. 
DMXL2 depletion leads to a significant downregulation 
of the majority of EMT genes (IQGAP1 5C, D and ZEB1, 
CD44, and RAC2 in Figure 5D) whilst tight junction marker 
ZO1 was upregulated (Figure 5C–5D). Strikingly, DMXL2 
depletion also resulted in a significant decrease in real time 
migration and invasion cells capacity (Figure 5E–5F). 
These data suggest that DMXL2 is involved in the 
aggressive phenotype exhibited by LTED cells. 
Notably, DMXL2 depletion did not affect cell viability 
(Supplementary Figure S2B). Next, we confirmed that 
DMXL2 siRNA mediated knock down using a 3D invasion 
assay. Remarkably, DMXL2 depletion significantly impairs 
the formation of pseudopodia and the invasion of the 
Figure 4: DMXL2 depletion is mirrored by V-ATPase inhibition. A. Representative immunofluorescence showing reduced 
Lysotracker staining following 72 hours DMXL2 depletion. Bars represent 400 uM B. Lysotracker staining of acidic intracellular 
compartments in LTED cells following Bafilomycin A1 treatment (6 hours). Bars represent 400 uM. C. Representative western blot 
showing Notch ICDs stop accumulating in the nucleus and the chromatin fraction following Bafilomycin A1 (BafA1) treatment in a time 
dependent manner D. q(RT) PCR mRNA of Notch targets levels following BafA1 treatment. In B, C, and D cells were treated with 125 pM 
of Bafilomycin A1. E. Notch targets are rescued by ectopic expression of Notch ICD. Cells were pre-treated for 6 hrs with 500 pM of BafA1 
followed by 24 hrs Notch ICD over-expression. Every experiment is an average of three independent experiments. Bars represent standard 
deviation (*) P < 0.05 (**) P < 0.01 (***) P < 0.001.
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extra-cellular matrix in LTED cells (Figure 5G). We then 
wanted to confirm these findings using Bafilomycin A1 
since we have shown that direct inhibition of the V-ATPase 
pump phenocopy DMXL2 depletion. Interestingly, main 
EMT targets are significantly reduced upon Bafilomycin A1 
treatment and the tight junction marker ZO1 is upregulated 
(Figure 5H). Furthermore, Bafilomycin A1 treatment 
significantly impairs invasion in our 3D invasion assay 
(Figure 5I). Moreover, in agreement with our previous 
results (Figure 4E) Notch ICD overexpression was sufficient 
Figure 5: DMXL2 regulates mesenchymal switch in LTED cells. A. Representative western blot showing EMT targets genes in 
LTED cells compared to MCF7 B. q(RT) PCR mRNA levels of EMT targets normalised to 28S C. Representative western blot showing 
regulation of EMT genes following DMXL2 knock down D. q(RT) PCR mRNA of EMT genes after siDMXL2 E, F. Knock down was 
performed on 6 well plate for 24/48 hours. Cells were harvested and counted. 40,000 were seeded on 16 wells ECM plates with/without 
matrigel (for invasion and migration respectively) and left migrating or invading for 48/24 hours respectively. The graphs represent the 
difference in cell number compared to siControl G. 3D Invasion assay organoids. Representative pictures of organoids embedded in matrigel 
after 5 days knock down (performed during the hanging time) at day 0 and 2. The graph represents the difference in the area between day 0 
(cells just embedded) and day 2 (cells left invading. Bars represent 400 uM. H. Bafilomycin A1 impairs cell invasion. Cells were treated as in 
4C. qRT-PCR mRNA for EMT genes is shown. I. Representative pictures of organoids. Medium containing 500 pM BafA1 was added to the 
medium for 48 hours after embedding the organoids in matrigel. Day 0 and day 2 images are shown. L. EMT targets are rescued by ectopic 
expression of Notch ICD. Cells were pre-treated for 6 hrs with 500 pM of BafA1 followed by 24 hours Notch ICD over-expression. Every 
experiment is an average of three independent experiments. Bars represent standard deviation (*) P < 0.05 (**) P < 0.01 (***) P < 0.001.
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to rescue EMT genes expression in Bafylomicin treated cells 
(Figure 5L). Altogether, these evidences strongly support 
DMXL2 as a major player in determining mesenchymal 
switch in our endocrine resistant cell line model.
DXML2 has a potential extracellular domain
The V-ATPase pump complex consists of two 
different domains of which one is a peripheral membrane 
sub-complex. DXML2 is thought to control the modulation 
of the pump assembly/disassembly process [41, 42]. 
We speculated that DMXL2 could also be a peripheral 
membrane protein. To test this, we first employed EZ-
Link Sulfo-NHS-LC-LC-Biotin to label cell surface 
proteins and confirm an increase of signal from DMXL2 
protein outside LTED cells membrane (Figure 6A). Next, 
we used several publicly available informatics predictive 
algorithms (e.g. MEMSAT, PSIPRED, TMHMM, TMPRED 
[43–46] to test if DMXL2 carries potential transmembrane 
domains. Notably, several algorithms predicted the same 
potential transmemembrane domain (Figure 6B and 
Supplementary Figure S3). We further investigated this 
possibility, using two different antibodies: one mapping onto 
the potential outer domain, and one mapping onto the putative 
cytoplasmic end (They were both fully characterised in 
Supplementary Figure S2A–2D). Live immunofluorescence 
without cell permeabilization shows that only the antibody 
interacting with the potential extra­cellular domain could 
detect DMXL2 (Figure 6C). Overall, these data strongly 
suggest that DMXL2 could be a peripheral membrane protein 
with a potentially targetable extracellular domain.
DISCUSSION
Here we demonstrate that DMXL2 overexpression 
drives Notch signalling and EMT transition in endocrine 
therapy resistant breast cancer cells. DMXL2 activity 
impinges on the V-ATPase pump and can be antagonized 
using siRNA or chemical inhibitors. More importantly, 
DMXL2 increases in vivo in patients who relapse 
following treatment with endocrine therapy.
Notch is involved in numerous pathways and plays 
a significant role in tumor progression and metastasis 
[10]. However, there is still a lack of understanding of the 
molecular details of Notch signalling, especially in cancer 
cells. On this ground, we investigated DMXL2 as it was 
recently discovered as a novel potential Notch regulator 
[22, 23]. We show that DMXL2 expression significantly 
correlates with the development of endocrine resistance. 
However we cannot exclude that a resistant pre­existent 
population with high levels of DMXL2 emerge during 
chronic exposure to treatment. At any rate our data provide 
novel insights that explain apparent contradictory results 
such as that ETR cells have enhanced Notch signalling 
while having lower total Notch receptors. This suggests the 
processing rate of the Notch receptors cleavage might be 
more accurate in predicting actual Notch signalling compared 
the total unprocessed protein levels. DMXL2 appears to be 
essential in this process as direct DMXL2 suppression or 
blockage of the V-ATPase activity result in an important 
reduction of NICD accumulation in the chromatin fraction.
Drug resistance is a major hurdle for patients with 
ERα breast cancer. A spectrum of published research 
supports Notch as a key player in drug resistance [18, 19, 
29, 47]; therefore targeting this pathway is becoming more 
and more attractive [48, 49]. The mechanisms behind drug 
resistance are not completely understood but increasing 
evidence suggests that resistant cells may epigenetically 
activate alternative pathways [19, 50]. Our model suggests 
that DMXL2 is upregulated in response to endocrine 
therapy treatment and contributes to a the more aggressive 
phenotype observed in these cells.
A recent work from Tuttle and colleagues uncovered a 
potential role of DMXL2 and V-ATPase in EMT/migration of 
neuronal crest in Zebrafish models. Based on these findings 
and on the highlight of our recent work [29], we wanted to 
explore the role of DMXL2 in driving the mesenchymal 
switch in therapy resistant breast cancer. We reveal for 
the first time that DMXL2 is responsible for driving the 
mesenchymal switch in ETR cells and that blocking DMXL2 
significantly impairs both migration and invasion. We also 
demonstrate that DMXL2 is a V-ATPase interacting partner 
Figure 6: DMXL2 has a potential extracellular domain. A. Western blot showing cells labeled with biotin and processed as 
described in material and methods. EGFR and Actin are used as controls B. Graphs showing DMXL2 putative transmembrane domain 
C. Representative live immunofluorescence images showing DMXL2 is detected only with the antibody interacting with the potential 
extracellular domain (AbCAm antibody). Bars represent 400 uM.
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and the pump acidification controls Notch signalling. Indeed, 
blocking V-ATPase using Bafilomicyn A1 mirrors DMXL2 
depletion and impairs Notch binding to the chromatin as well 
as invasion. DMXL2 overexpression in ETR cell lines, and 
its implication in metastatic development, gave us the idea 
of looking in the clinical setting. To our knowledge, this is 
the first report indicating that DMXL2 protein is present in 
patients with ERα breast cancer. Notably, DMXL2 increases 
dramatically during breast cancer progression, in agreement 
with our cell line model.
V-ATPase inhibition, through Bafilomycin A1, causes 
tumor regression and metastasis inhibition in vivo and in vitro 
[51]. Based on these facts, we reasoned that manipulating 
Notch via DMXL2 inhibition could be an exciting route that 
warrants further investigation. At the moment, the approach 
taken to target Notch signalling had been through the use 
of GSIs that inhibit signalling by all four Notch receptors 
[52, 53]. Our recent works showed that using monoclonal 
antibodies to target the extra­cellular domain of Nicastrin, the 
catalytic subunit of the GS complex, greatly reduced the tumor 
bulk in vivo and limits invasion and migration in vitro [29, 
54]. Here, we show that DMXL2 likely has an extracellular 
portion. This warrants further investigation focusing on the 
development of monoclonal antibodies targeting DMXL2 as 
an alternative option to block Notch in breast cancer.
MATERIALS AND METHODS
Cell culture
Cells were originated as previously described [28]. 
MCF7 cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% fetal calf 
serum (FCS). LTED were maintained in phenol-red 
free DMEM containing 10% charcoal stripped fetal calf 
serum (SFCS). Both media were supplemented with 
2 mM L-glutamine, 100 units/mL penicillin, 0.1 mg/mL. 
10−8 M Estradiol (E2758 Sigma) was added routinely to 
MCF7. Cells used in Figures 1 and 2 and named “clone 2”, 
were independently derived [19]. 10−7 Tamoxifen (H7904 
Sigma) and Fulvestrant (I4409 Sigma) were added to 
TAMR and FULVR cells.
Migration and invasion assay
This assay was performed as previously described 
(Nguyen et al., under revision). Briefly, real time cell 
analysis (RTCA) was carried on using xCELLigence 
technology (Cambridge Bioscience), and 40,000 cells 
were seeded on a well of 16-transwell CIM-PLATES 
with/without matrigel to monitor migration and invasion 
respectively. Prior to each experiment, cells were subjected 
to 48/24 hrs DMXL2 knock down, harvested, counted, 
and then allowed to migrate or invade for 24–48 hours 
respectively (total knock down 72 hrs). Serum free medium 
was used to resuspend and seed the cells, and 10% FCS or 
DC/FCS full medium was used as chemo-attractant.
RNA extraction and real time RT_PCR
RNA extraction and cDNA preparation were 
performed as previously described [29]. Briefly, QIAGEN 
columns were used for RNA extraction. 2ug were 
retro-transcribed using High Capacity cDNA Reverse 
Transcription (AB 4368814 Applied Biosystem). 2X 
SYBR GREEN mix (4309155 Invitrogen) was used 
to perform quantitative real time RT-PCR. The PCR 
amplification was as follows: 95°C (10 min), 95°C (10 sec), 
60°C (30 sec), 72°C (30 seconds), 40 cycles followed by 
melting curve analysis. Melting curves were analysed after 
40 cycles. Expression levels of each gene were evaluated 
using comparative threshold cycle (Ct) method using the 
2-ΔΔCt method with normalization to 28S housekeeping 
gene. Primers sequences are available upon request.
siRNA
Silencers Select Small interfering RNA (siRNA) 
against DMXL2 were purchased from Invitrogen (s23533, 
s23534). Silencer Select Negative 1 was used as control 
(4404020). Briefly, 300,000 cells were seeded on a 6 well 
plate. The following day Lipofectamine 2000 (11668) was 
used according to the manufacturer protocol. 5nM siRNA 
were used as final concentration. RNA and proteins were 
analysed 24 and 72 hours later respectively.
Overexpression
Notch1, Notch3 and Notch4 ICDs were a kind gift 
from Keith Brennan. Plasmids were fully sequenced. 
Lipofectamine 2000 was used according to the 
instructions. 300,000 cells were seeded on day 1. The 
following day, 1 ug of DNA was used for transfection. 
Cells were harvested and lysed 24 hrs later.
Rescue experiment
LTED cells (200,000) were seeded on 6 well plates. 
The following day 500pM Bafilomycin A1 was added to 
the medium. After 6 hours, cells were transfected with 1 ug 
of Notch3, 4 plasmid using Lipofectamine 2000 according 
to the manufacturer instructions. 24 hours later, mRNA 
was extracted according to the manufacturer instructions 
(QIAGEN). DMSO was used as control.
3D organoids assay (hanging drop assay)
A 3D assay was performed as previously described 
(Nguyen et al. under revision). Briefly, 250,000 cells 
were resuspended in 1ml of medium. Drops (20 ul) were 
placed onto the lid of a 10 cm dish, then the lid was flipped 
onto of the dish, containing 5 ml of media to prevent 
evaporation. The dish was then incubated for 5 days at 
37°C. On day 5, the newly formed organoids were mounted 
on 10ul phenol red free matrigel (356237) on a coverslip 
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in a 24 well plate. Matrigel was left for 1 hr at 37°C 
in the incubator to solidify, then 500 ul of full medium was 
added. Pictures were taken at day 0 and day 2. In knock down 
experiments, siDMXL2 or siControl were added to the cells 
before making the drops. In Bafilomycin A1 experiments, the 
drug was added to the medium on day 0 for 48 hours.
Immunofluorescence
Briefly, cells were seeded on coverslips on a 6 well 
plate. On the final day, cells were washed twice with room 
temperature PBS and 4% PFA/PBS was added for 15 
minutes. Cells were washed twice with PBS and NH4Cl 
was added as quencher. 1% Triton/PBS was added for 5 
minutes. 10% BSA/PBS was used as blocking reagent. 5% 
BSA/PBS was used to dilute antibodies and Alexa-fluor 
488 or 594labelled anti-rabbit or anti-mouse secondary 
antibodies. Cells were mounted in mounting medium 
(MOWIOL) containing 4’,6-diamidino-2-phenylindole. 
For live immunofluorescence, no fixative was used. 
Pictures were acquired using EVOS microscope system 
(Advanced Microscopy Group, Bothell, WA, USA) or 
Leica SP5 confocal microscope.
Antibodies-drugs
We used two antibodies against DMXL2 (24415-1-AP 
from Proteintech) for western blot and immunofluorescence 
and ab122552 (abCam) for IHC and immunofluorescence. 
Antibodies against Notch1 and Notch3 were purchased from 
Cell Signalling (3608, and 2889) and Notch4 was purchased 
from Santa Cruz (Sc-5594 H-225). Actin and V5 antibodies 
were purchased from abCam (ab6276 and ab9116). ZEB1 
(3396), ZO1 (8193), E-Cadherin (3195), and IQGAP1 (2293) 
antibodies were purchased from Cell Signalling. Bafilomycin 
A1 was purchased from Sigma (B1793). TBP was purchased 
from Santa Cruz. LysoTracker (LysoTracker® Red DND-99 
Life Technologies) was used according to the manufacturer 
protocol for labelling acidic organelles in live cells following 
Bafilomycin A1 and DMXL2 siRNA treatments. In knock 
down experiments, the LysoTracker was added after 72 
hours. Estradiol for culturing MCF7 was also purchased from 
Sigma and diluted in 100% Ethanol in a final concentration 
of 10−7M. Biotinylation assay was performed according 
to the manufacturer protocol (21435 Thermo Scientific). 
GSI was purchased from Pfizer, Inc (New York, NY, USA) 
(PF03084014). Dll4 ligand was purchased from abCAm 
(108557).
Western blot and fractionation
RIPA (Sigma) was used to prepare total lysate. 
Fractionation method was performed as previously 
described [55]. Bicinchoninic Acid (BCA) assay 
(Thermo Scientific) was used to determine protein 
concentration. Equal amounts of lysates were subjected to 
immunoblotting on SDS-PAGE. IRDyes IR680, IR680-LT, 
or IR800 (LI-COR) were used as secondary antibodies. LI-
COR Odyssey 2.1 system was used to visualise proteins. 
16-bit images were analyzed and quantified using Image J.
Tissue microarray (TMA) of paired primary and 
secondary breast cancers
Twenty primary breast carcinomas with a paired 
metastasis were acquired from the pathology archives of 
Charing Cross Hospital, London, UK. A tissue microarray was 
constructed using a manual microarray (Beecher) and 0.6 mm 
punches. The tissue microarray was immunohistochemically 
profiled for DMXL2 and other biological antibodies as 
previously described (ref ?). DMXL2 rabbit antibody 
(ab122552, abCam) was optimized to a working concentration 
(1:500 in PBS); utilizing tissue sections (5 μm). Antigen 
retrieval was performed using 0.01M citrate buffer, pH 6.0 
followed by blocking in 0.3% hydrogen peroxide in PBS, then 
in normal goat serum (20 μl per ml) for 30 min. The primary 
antibody was incubated overnight at 4°C, and then detected 
using anti-rabbit secondary antibody (Vector Laboratories), 
Vectastain Elite peroxidase ABC kit, and ImmPACT DAB 
kit (Vector Laboratories). Subsequently, 4 μm TMA sections 
were immuno­stained using the optimized staining protocol, 
including negative controls (omission of the primary antibody). 
Staining was scored based on the H-score and Allred Quick 
score (LM, MF). Cores were scored using an H-score by 
three independent investigators (including one consultant 
pathologist) blinded to the clinico-pathological characteristics 
of patients. H = (3 × % of strongly stained cells) + (2 × % of 
moderately stained cells) + (1 × % of weakly stained cells) + 
(0 × % of cells without staining). This gave a score ranging 
from total absence of DMXL2 in the tumor compartment 
(H-score 0) to DMXL2 expression in tumor cells equivalent to 
surrounding normal and stromal cells (H-score 300).
Statistical analysis
Two-tailed paired T­test was used to generate 
P-values (indicated as *P = 0.05, **P = 0.01, and ***P = 
0.001). Anova test with Tukey’s post test was used to generate 
P-values for the rescue experiment (*P = 0.05, **P = 0.01).
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